DOW JONES, A NEWS CORP COMPANY
News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services.
DOW JONES
  • Barron's
  • BigCharts
  • DJX
  • Dow Jones Newswires
  • Factiva
  • Financial News
  • Mansion Global
  • MarketWatch
  • Newsmart
  • NewsPlus
  • Private Markets
  • Risk & Compliance
  • WSJ.com
  • WSJ Pro
  • WSJ Conference
  • WSJ Video
NEWS CORP
  • Big Decisions
  • Business Spectator
  • Checkout51
  • Harper Collins
  • New York Post
  • PropTiger
  • REA
  • realtor.com
  • Storyful
  • The Australian
  • The Sun
  • The Times
ダウ平均 ▲
17539.16 0.22%
  S&P 500 ▲
2054.63 0.11%
  ナスダック ▲
4789.60 0.42%
  米10年債 ▲
1/32 yield 1.839%
  原油 ▲
47.86 -1.14%
  ユーロ/ドル ▲
1.1197 -0.26%
 
Subscribe Now Sign In
The Wall Street Journal
日本 (Japan)
  • U.S.
  • Asia
  • Europe
  • India
  • América Latina
  • Brasil
  • 中国 (China)
  • 日本 (Japan)
2016年5月23日
Sections
My Journal
  • ホーム
  • 経済
  • マーケット
  • ビジネス
  • テクノロジー
  • 国際
  • 国内
  • オピニオン・社説
  • ライフ
  • バロンズ
  • SHOW ALL SECTIONS HIDE ALL SECTIONS
    • 経済
      • 金融政策ウォッチ
      • Heard on the Street
    • マーケット
      • マーケットデータ
    • テクノロジー
      • ガジェットレビュー
    • 国際
      • 北米
      • 米大統領選特集
      • アジア・オセアニア
      • 欧州
      • 中東・アフリカ
      • China's World
      • China Real Time Report
    • 国内
      • 編集長インタビュー
    • オピニオン・社説
      • オピニオ ン
      • 社説
    • ライフ
      • キャリア
      • ヘルス
    • バロンズ
      • 日本市場
      • IT注目銘柄
      • インタビュー
      • コラム
    HIDE ALL SECTIONS
Sign In
  • ホーム
  • 経済
    • 金融政策ウォッチ
    • Heard on the Street
  • マーケット
    • マーケットデータ
  • ビジネス
  • テクノロジー
    • ガジェットレビュー
  • 国際
    • 北米
    • 米大統領選特集
    • アジア・オセアニア
    • 欧州
    • 中東・アフリカ
    • China's World
    • China Real Time Report
  • 国内
    • 編集長インタビュー
  • オピニオン・社説
    • オピニオ ン
    • 社説
  • ライフ
    • キャリア
    • ヘルス
  • バロンズ
    • 日本市場
    • IT注目銘柄
    • インタビュー
    • コラム
Search
Subscribe Sign In

Merck & Co. Inc. MRK (U.S.: NYSE)

View All companies
  • REAL TIME 10:11 AM EDT 05/23/16
  • $55.08 USD
  • -0.03 -0.05%
  • Volume 670,975
  • Volume 670,975
  • 65 Day Avg Vol 8,919,724
  • 1 Day Range 54.78 - 55.23
  • 52 Week Range 45.69 - 61.70 (08/24/15 - 06/01/15)
  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • YTD
  • 1 Y
  • 3 Y
  • $
  • %
Advanced Charting Compare
  • Compare to Benchmark:
  • DJIA
  • S&P 500
  • GLOBAL DOW
  • NASDAQ
  • Health Care/Life Sciences
  • Compare to
  • Open 55.00
  • Prior Close 55.11 (05/20/16)
  • 1 Day
  • MRK -0.05%
  • DJIA 0.22%
  • S&P 500 0.12%
  • Health Care/Life Sciences 1.05%
  • Overview

News Merck & Co. Inc.MRK

    • 1 hour ago
    • Press Release
    Merck Foundation Announces the Alliance to Advance Patient-Centered Cancer Care, a $15 Million Initiative to Improve Access to High-Quality Cancer Care in Underserved Communities in the United States
    • Press Release
    • 05/18/16
    • Press Release
    New KEYTRUDA(R) (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting
    • Press Release
    • 05/18/16
    • Dow Jones Newswires
    New Hope for Melanoma Patients
    • Dow Jones Newswires
    • 05/18/16
    • The Wall Street Journal
    New Hope for Melanoma Patients
    • The Wall Street Journal
    • 05/16/16
    • Press Release
    New KEYTRUDA(R) (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer
    • Press Release
    • 05/12/16
    • Press Release
    Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76(th) Scientific Sessions of the American Diabetes Association
    • Press Release
    • 05/10/16
    • MarketWatch.com
    Feds investigate drugmakers’ ties to pharmacy-benefit managers
    • MarketWatch.com
    • 05/10/16
    • MarketWatch.com
    U.S. investigates Merck, J&J and Endo over pharmacy-benefit contracts
    • MarketWatch.com
    • 05/10/16
    • Barron's
    Three Big Pharma Stocks Headed Higher
    • Barron's
    • 05/05/16
    • The Wall Street Journal
    Fading Oil Rally Keeps Lid on U.S. Stocks
    • The Wall Street Journal
    • 05/05/16
    • Dow Jones Newswires
    Merck Revenue Falls on Generic Competition, Currency -- 2nd Update
    • Dow Jones Newswires
    • 05/05/16
    • The Wall Street Journal
    Merck Revenue Falls on Generic Competition
    • The Wall Street Journal
    • 05/05/16
    • WSJ Blogs
    Stocks to Watch: Alibaba, Regeneron, Merck, AmerisourceBergen
    • WSJ Blogs
    • 05/05/16
    • Dow Jones Newswires
    U.S. Hot Stocks: Hot Stocks to Watch
    • Dow Jones Newswires
    • 05/05/16
    • WSJ Blogs
    Pullback Among Chip Makers Is Latest Reason to Doubt the Rally — Morning MoneyBeat
    • WSJ Blogs
    • 05/05/16
    • Dow Jones Newswires
    Merck Revenue Falls on Generic Competition, Currency
    • Dow Jones Newswires
    • 05/05/16
    • Press Release
    Merck Announces First-Quarter 2016 Financial Results
    • Press Release
    • 05/05/16
    • Barron's
    Merck: Good Time to Buy
    • Barron's
    • 05/04/16
    • Press Release
    Merck to Present at the Deutsche Bank 41st Annual Health Care Conference
    • Press Release
    • 05/03/16
    • The Wall Street Journal
    Merck Earnings: What to Watch
    • The Wall Street Journal
    • 05/02/16
    • The Wall Street Journal
    Judge Allows More Evidence in Gilead-Merck Patent Dispute
    • The Wall Street Journal
    • 05/02/16
    • Dow Jones Newswires
    Judge Allows More Evidence in Patent Dispute After Gilead Says Merck Attorney Lied
    • Dow Jones Newswires
    • 04/30/16
    • Barron's
    Snapchat Keeps Climbing
    • Barron's
    • 04/28/16
    • Dow Jones Newswires
    Gilead Reports Drop in Hepatitis C Drug Revenue -- Update
    • Dow Jones Newswires
    • 04/28/16
    • The Wall Street Journal
    Gilead Reports Drop in Hepatitis C Drug Revenue
    • The Wall Street Journal
    • 04/28/16
    • Dow Jones Newswires
    Gilead Reports Drop in Hepatitis C Drug Revenue
    • Dow Jones Newswires
    • 04/28/16
    • Press Release
    Christina Applegate and Merck Urge Insomnia Sufferers to Learn "Why They're So Awake"
    • Press Release
    • 04/27/16
    • Press Release
    Merck, the American Diabetes Association and America's Diabetes Challenge Celebrity Voices Unite to Take on National Health Epidemic
    • Press Release
    • 04/26/16
    • Press Release
    Journal of the American Medical Association Publishes Phase III Data from Allergic Asthma Trial with ALK's House Dust Mite SLIT-tablet, ACARIZAX(R)
    • Press Release
    • 04/19/16
    • Press Release
    Merck Animal Health to Acquire Worldwide Rights to Whisper(R) Veterinary Stethoscope System
    • Press Release
    • 04/19/16
    • Press Release
    Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting
    • Press Release
    • 04/18/16
    • Press Release
    Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA(R) (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)
    • Press Release
    • 04/16/16
    • Press Release
    Merck Announces Results From Phase 3 Studies of ZEPATIER(TM) (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress(TM)
    • Press Release
    • 04/14/16
    • Press Release
    Merck's ZEPATIER(TM) (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
    • Press Release
    • 04/13/16
    • Press Release
    FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA(R) (pembrolizumab) in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review
    • Press Release
    • 04/13/16
    • Press Release
    License application for investigational house dust mite SLIT-tablet accepted for review by FDA
    • Press Release
    • 04/08/16
    • Press Release
    Merck to Hold First-Quarter 2016 Sales and Earnings Conference Call on May 5
    • Press Release
    • 04/07/16
    • Press Release
    Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More Than 30 Data Presentations at ECCMID 2016
    • Press Release
    • 04/06/16
    • Press Release
    Merck to Present New Data for KEYTRUDA(R) (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting
    • Press Release
    • 04/05/16
    • Press Release
    Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
    • Press Release
load more
Key Stock Data
?
P/E Ratio (TTM)
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Earnings Per Share (TTM)
A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization
Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
Shares Outstanding
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Public Float
The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
Dividend Yield
A company's dividend expressed as a percentage of its current stock price.

Key Stock Data

  • P/E Ratio (TTM)
    33.77 (05/23/16)
  • EPS (TTM)
    $1.63
  • Market Cap
    $152.55 B
  • Shares Outstanding
    2.77 B
  • Public Float
    2.77 B
  • Yield
    3.34% (05/23/16)
  • Latest Dividend
    $0.46 (04/07/16)
  • Ex-Dividend Date
    03/11/16
?
Shares Sold Short
The total number of shares of a security that have been sold short and not yet repurchased.
Change from Last
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Percent of Float
Total short positions relative to the number of shares available to trade.

Short Interest (04/29/16)

  • Shares Sold Short
    27.68 M
  • Change from Last
    -8.93%
  • Percent of Float
    1.00%
?
Money Flow Uptick/Downtick Ratio
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

  • Uptick/Downtick Trade Ratio
    0 2
    0.40
    Net Money Flow ($)
    -6.07 M

    Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.

Advertisement

Competitors MRK

Company Change P/E (TTM)
GSK

GlaxoSmithKline PLC ADR

+0.31% +0.13 111.08
NVS

Novartis AG ADR

+2.79% +2.12 28.18
ABT

Abbott Laboratories

-0.03% -0.01 23.37
BMY

Bristol-Myers Squibb Co.

-0.93% -0.66 72.24
JNJ

Johnson & Johnson

-0.30% -0.34 20.43
LLY

Eli Lilly & Co.

+0.01% +0.01 34.72
PFE

Pfizer Inc.

+0.15% +0.05 24.96
RHHVF

Roche Holding AG Part. Cert.

+1.02% +2.50 23.19
SNY

Sanofi ADR

-0.94% -0.37 22.02
TEVA

Teva Pharmaceutical Industries Ltd. ADR

-0.43% -0.22 25.73
  • More information on MRK
  • Competitor Data Provided By: capital cube

Profile MRK

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. It is a global research-driven pharmaceutical company that discovers, develops, manufactures and...

2000 Galloping Hill Road
Kenilworth New Jersey 07033
United States

  • Website
  • Map
  • Employees 68,000
    Sector Pharmaceuticals
  • Sales or Revenue 38.77 B
    Industry Health Care/Life Sciences
  • 1Y Sales Change -7.92%
    Fiscal Year Ends December 31 Download Reports
  • Kenneth C. Frazier Chairman, President & Chief Executive Officer
  • Robert M. Davis Chief Financial Officer & Executive Vice President
  • Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
  • Clark Golestani Chief Information Officer & Executive VP
  • More

Research & Ratings Merck & Co. Inc.MRK

Per-Share Earnings, Actuals and Estimates

  • Quarterly
  • Annual
MRK will report FY 2016 earnings on false MRK will report Q2 earnings on 07/26/2016
Actual Analyst Range Consensus
1.10 1.00 0.90 0.80
Actual 0.86
0.81
Actual 0.96
0.92
Actual 0.93
0.91
Actual 0.89
0.85
0.91
0.98
Q22015 Q3 Q4 Q12016 Q2 Q3
6.00 4.00 2.00 0.00
Actual 1.56
3.57
3.72
3.76
4.09
FY 2015 FY 2016 FY 2017 FY 2018
Q2 2016 Estimate Trends
Current: $0.91
1 month ago: $0.91
3 months ago: $0.90
Q3 2016 Estimate Trends
Current: $0.98
1 month ago: $0.98
3 months ago: $0.98
FY 2016 Estimate Trends
Current: $3.72
1 month ago: $3.70
3 months ago: $3.70
FY 2017 Estimate Trends
Current: $3.76
1 month ago: $3.78
3 months ago: $3.79
  • More

Financials Merck & Co. Inc.MRK

  • Quarterly
  • Annual

Net Income

0 500M 1B 1.5B 2B
Mar 2015 Jun 2015 Sep 2015 Dec 2015 Mar 2016
0 3B 6B 9B 12B
'11 '12 '13 '14 '15
Mar 2016 5-quarter trend
Net Income Growth +18.05%
Sales or Revenue 9.17 B
Sales or Revenue Growth -0.95%
EBITDA +3.58 B
2015 5-year trend
Net Income Growth -62.73%
Sales or Revenue 38.77 B
Sales or Revenue Growth -7.92%
EBITDA +13.78 B
  • More
  • Overview

Notes & Data Providers

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.

Advertisement
  • Wall Street Journal
  • 日本 (Japan)
    • U.S.
    • Asia
    • Europe
    • India
    • América Latina
    • Brasil
    • 中国 (China)
    • 日本 (Japan)
  • Subscribe NowSign In

  • WSJ Membership Benefits
  • Download WSJ Apps
  • Customer Center
  • Legal Policies
  • Subscribe
  • Sign In
  • TOP«
  • Customer Service

  • Customer Center
  • Contact Us
  • About Houjin Subscribing
  • 学生割引購読
  • About Us
  • Ads

  • About Ads
  • Tools & Features

  • iPhone App
  • iPad App
  • Android App
  • Newsletter
  • About Japanese Blog Parts
  • More

  • Events
  • Jobs at WSJ
    • Facebook
    • Twitter
    • Google+
    • YouTube
    • Podcasts
    • Snapchat
    • GooglePlay
    • AppStore
    • Windows10
  • Dow Jones Products
  • Barron's
  • BigCharts
  • DJX
  • Dow Jones Newswires
  • Factiva
  • Financial News
  • Mansion Global
  • MarketWatch
  • Private Markets
  • realtor.com
  • Risk & Compliance
  • WSJ Conference
  • WSJ Pro Central Banking
  • WSJ Video
  • WSJ Wine
  • BallBall
  • Privacy Policy
  • Cookie Policy
  • Tokusyo
  • Data Policy
  • Subscriber Agreement & Terms of Use
  • Copyright ©2016 Dow Jones & Company, Inc. All Rights Reserved.